Quick Answer
KALA BIO, Inc. reported Total Revenue of $0.00 for fiscal year 2017.
KALA BIO, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$38.51M +8.7% |
-$42.20M +5.9% |
-$44.82M +68.6% |
-$142.60M -36.7% |
-$104.33M -10.6% |
-$94.35M -41.4% |
| Diluted EPS | -$10.15 +41.5% |
-$17.35 +41.1% |
-$29.48 +72.8% |
-$108.32 -5343.2% |
-$1.99 | — |
| Total Assets | $55.48M -0.8% |
$55.95M -35.6% |
$86.82M -37.7% |
$139.43M -37.1% |
$221.61M +43.6% |
$154.32M -30.2% |
| Cash and Equivalents | $51.18M +0.6% |
$50.90M -27.8% |
$70.50M -23.5% |
$92.14M +19.2% |
$77.26M -9.6% |
$85.45M |
| Long-Term Debt | $20.10M -41.2% |
$34.19M -9.9% |
$37.94M -51.9% |
$78.93M +9.3% |
$72.24M +1.5% |
$71.18M +1.4% |
| Stockholders Equity | $12.33M +64.3% |
$7.50M -60.5% |
$18.97M +12.9% |
$16.80M -83.2% |
$100.00M +236.8% |
$29.69M -71.7% |
| R&D Expense | — | — | — | — | $18.35M -32.7% |
$27.27M -6.9% |
| Operating Income | -$40.98M -3.3% |
-$39.66M +51.5% |
-$81.71M +37.3% |
-$130.25M -35.3% |
-$96.23M -9.1% |
-$88.22M -36.3% |
| Shares Outstanding | 6.09M +120.7% |
2.76M +275937100.0% |
1 -100.0% |
1.32M -97.8% |
58.92M +63.3% |
36.09M +6.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$7.56M | +15.5% | +32.2% |
| Diluted EPS | September 30, 2025 | -$1.07 | +44.6% | +37.4% |
| Total Assets | September 30, 2025 | $25.02M | -53.7% | -30.6% |
| Cash and Equivalents | September 30, 2025 | $21.10M | -57.1% | -34.0% |
| Long-Term Debt | June 30, 2025 | $18.79M | -17.7% | +24.2% |
| Stockholders Equity | September 30, 2025 | -$8.66M | -226.3% | -170.3% |
| R&D Expense | September 30, 2025 | $6.13M | +18.6% | -1.7% |
| Operating Income | September 30, 2025 | -$7.24M | +27.5% | +34.4% |
| Shares Outstanding | September 30, 2025 | 7.43M | +61.2% | +11.3% |
- KALA BIO, Inc. reported Total Revenue of $0.00 for fiscal year 2017.
- KALA BIO, Inc. reported Net Income of -$38.51 million for fiscal year 2024.
- KALA BIO, Inc. showed an increase of +8.7% in Net Income compared to the prior fiscal year.
- KALA BIO, Inc. reported Diluted EPS of $10.15 per share (loss) for fiscal year 2024.
- KALA BIO, Inc. showed an increase of +41.5% in Diluted EPS compared to the prior fiscal year.
- KALA BIO, Inc. reported Total Assets of $55.48 million for fiscal year 2024.
- KALA BIO, Inc. showed a decrease of -0.8% in Total Assets compared to the prior fiscal year.
- KALA BIO, Inc. reported Cash and Equivalents of $51.18 million for fiscal year 2024.
- KALA BIO, Inc. showed an increase of +0.6% in Cash and Equivalents compared to the prior fiscal year.
- KALA BIO, Inc. reported Long-Term Debt of $20.10 million for fiscal year 2024.
- KALA BIO, Inc. showed a decrease of -41.2% in Long-Term Debt compared to the prior fiscal year.
- KALA BIO, Inc. reported Stockholders Equity of $12.33 million for fiscal year 2024.
- KALA BIO, Inc. showed an increase of +64.3% in Stockholders Equity compared to the prior fiscal year.
- KALA BIO, Inc. reported R&D Expense of $18.35 million for fiscal year 2020.
- KALA BIO, Inc. showed a decrease of -32.7% in R&D Expense compared to the prior fiscal year.
- KALA BIO, Inc. reported Operating Income of -$40.98 million for fiscal year 2024.
- KALA BIO, Inc. showed a decrease of -3.3% in Operating Income compared to the prior fiscal year.
- KALA BIO, Inc. reported Shares Outstanding of 6.09 million shares for fiscal year 2024.
- KALA BIO, Inc. showed an increase of +120.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: